Merck Inc., known as MSD outside of the United States and Canada, announced positive data from multiple Phase II studies evaluating V 116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa
Merck has announced that the Biologics License Application for V 503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been...
Zealand Pharma announced it has entered into an asset purchase agreement with MannKind Corporation ( to sell the V-Go insulin delivery device for $10 million and additional sales-based milestones).
Merck has announced that the pivotal efficacy trial for V 503 (HPV vaccine) is complete, the primary endpoints have been...
Merck Inc.,, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V 590 and V 591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK 4482 and MK 7110.